Beam Therapeutics Appoints Sravan Emany as New CFO, Shares Up

Zacks12-09

Shares of Beam Therapeutics Inc. BEAM were up 5.5% on Dec. 6 after the company announced that it has appointed Sravan K. Emany as its new chief financial officer (CFO). He will assume his new role on ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2490799937?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/b7YQi_HTDu1GkQZqPUqgyw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/59b208c03ab625710a229f805a232093","is_english":true,"pubTime":"2024-12-09 21:23","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2490799937","market":"us","top_or_hot":-1,"title":"Beam Therapeutics Appoints Sravan Emany as New CFO, Shares Up","media":"Zacks","content":"<div>\n<p>Shares of Beam Therapeutics Inc. BEAM were up 5.5% on Dec. 6 after the company announced that it has appointed Sravan K. Emany as its new chief financial officer (CFO).\nHe will assume his new role on ...</p>\n\n<a href=\"https://finance.yahoo.com/news/beam-therapeutics-appoints-sravan-emany-132300768.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Beam Therapeutics Appoints Sravan Emany as New CFO, Shares Up</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBeam Therapeutics Appoints Sravan Emany as New CFO, Shares Up\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-09 21:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/beam-therapeutics-appoints-sravan-emany-132300768.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Beam Therapeutics Inc. BEAM were up 5.5% on Dec. 6 after the company announced that it has appointed Sravan K. Emany as its new chief financial officer (CFO).\nHe will assume his new role on ...</p>\n\n<a href=\"https://finance.yahoo.com/news/beam-therapeutics-appoints-sravan-emany-132300768.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1162221912.USD","symbol_name":"FRANKLIN INCOME \"A\" (USD) ACC","start_time":0,"source_url":"https://finance.yahoo.com/news/beam-therapeutics-appoints-sravan-emany-132300768.html","article_id":"2490799937","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/b7YQi_HTDu1GkQZqPUqgyw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/59b208c03ab625710a229f805a232093"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2490799937","pubTimestamp":1733750580,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Shares of Beam Therapeutics Inc. BEAM were up 5.5% on Dec. 6 after the company announced that it has appointed Sravan K. Emany as its new chief financial officer .He will assume his new role on Dec. 19, 2024.Emany most recently served as CFO and the chief operating officer at Ironwood Pharmaceuticals. He previously held senior leadership positions at Integra LifeSciences Holdings Corporation, a healthcare company, and also worked as an investment banker at Bank of America and BofA Securities.Emany also held other financial roles at Goldman Sachs and Morgan Stanley and served on the board of directors of Assertio Holdings.BEAM’s erstwhile CFO, Terry-Ann Burrell, stepped down from her role effective Aug. 9, 2024.Beam Therapeutics is developing its leading ex-vivo genome-editing candidate, BEAM-101, in the phase I/II BEACON study for the treatment of adult patients with sickle cell disease .Treatment with BEAM-101 also demonstrated rapid neutrophil and platelet engraftment and normalized ","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","BK4535":"淡马锡持仓","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","LU2028103732.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AMG\" (USD) INC","LU2089284900.SGD":"Allianz Global Sustainability Cl AM Dis H2-SGD","LU0267386448.USD":"FIDELITY FIRST ALL COUNTRY WORLD \"A\" (USD) INC","LU0158827781.USD":" ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (USD) ACC","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","BK4588":"碎股","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","LU1363072403.SGD":"Fidelity Global Financial Services A-ACC-SGD","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","LU0106831901.USD":"贝莱德世界金融基金A2","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","CFO":"VictoryShares US 500 Enhanced Volatility Wtd ETF","BK4505":"高瓴资本持仓","CSTL":"Castle Biosciences, Inc.","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","BK4581":"高盛持仓","LU0158827948.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"A\" (USD) INC","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","BK4504":"桥水持仓","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","LU0225283273.USD":"SCHRODER ISF GLOBAL EQUITY ALPHA \"A\" (USD) ACC","LU2089283258.USD":"安联环球可持续基金Cl AM Dis","SCD":"LMP Capital & Income Fund","LU0971096721.USD":"富达环球金融服务 A","LU1548497426.USD":"安联环球人工智能AT Acc","LU2111349929.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (HKD) INC","BK4127":"投资银行业与经纪业","IMCR":"Immunocore Holdings plc","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU1668664300.SGD":"Blackrock World Financials A2 SGD-H","BK4516":"特朗普概念","SPRO":"Spero Therapeutics Inc.","LU1720051108.HKD":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC","LU2271345857.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (HKD) ACC","LENZ":"Therapeutics","LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","BEAM":"Beam Therapeutics, Inc.","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","BK4556":"基因编辑","BK4139":"生物科技","LU2023251221.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (USD) INC","LU0098860793.USD":"FRANKLIN INCOME \"A\" INC","BK4196":"保健护理服务"},"translate_title":"Beam Therapeutics任命Sravan Emany为新任首席财务官，股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SPRO":1,"LENZ":1,"IMCR":1,"CSTL":1,"CFO":1,"SCD":1,"BEAM":0.9},"content_text":"Shares of Beam Therapeutics Inc. BEAM were up 5.5% on Dec. 6 after the company announced that it has appointed Sravan K. Emany as its new chief financial officer (CFO).\nHe will assume his new role on Dec. 19, 2024.\nEmany most recently served as CFO and the chief operating officer at Ironwood Pharmaceuticals. He previously held senior leadership positions at Integra LifeSciences Holdings Corporation, a healthcare company, and also worked as an investment banker at Bank of America and BofA Securities.\nEmany also held other financial roles at Goldman Sachs and Morgan Stanley and served on the board of directors of Assertio Holdings.\nBEAM’s erstwhile CFO, Terry-Ann Burrell, stepped down from her role effective Aug. 9, 2024.\nBEAM's Price Performance\nYear to date, shares of Beam Therapeutics have decreased 1.8% compared with the industry’s decline of 7.5%.\nImage Source: Zacks Investment Research\nBEAM’s pipeline of gene editing therapies is based on its proprietary base editing technology. The company is advancing its base editing technology across three disease area portfolios, namely, hematology, immunology/oncology and genetic diseases.\nBEAM's Recent Pipeline Updates\nBeam Therapeutics is developing its leading ex-vivo genome-editing candidate, BEAM-101, in the phase I/II BEACON study for the treatment of adult patients with sickle cell disease (SCD).\nIn a separate press release, the company announced new safety and efficacy data from the BEACON study on BEAM-101 in SCD patients with severe vaso-occlusive crises (VOCs).\nTo date, more than 35 patients have been enrolled in the BEACON study investigating BEAM-101 for the treatment of SCD and out of these 11 patients have been dosed. Seven patients were treated with BEAM-101 in the study as of the data cut-off date of Oct 28, 2024 and included in the safety and efficacy analysis.\nData from the same showed that treatment with BEAM-101 led to a robust and durable increase in fetal hemoglobin (HbF) of more than 60% and a reduction in sickle hemoglobin (HbS) to less than 40%.\nTreatment with BEAM-101 also demonstrated rapid neutrophil and platelet engraftment and normalized or improved markers of hemolysis in all the patients.\nThe data suggested that the initial safety profile of BEAM-101 was consistent with busulfan conditioning and autologous hematopoietic stem cell transplantation.\nBesides BEAM-101, BEAM is also expanding its genetic disease pipeline by developing BEAM-301 and BEAM-302 for treating glycogen storage disease Type Ia and alpha-1 antitrypsin deficiency, respectively.\nWith the ongoing studies on its pipeline candidates, it remains to be seen how the leadership transition helps Beam Therapeutics in developing a differentiated class of precision genetic medicines and driving long-term growth.\nBEAM's Zacks Rank & Key Picks\nBeam Therapeutics currently carries a Zacks Rank #3 (Hold).\nSome better-ranked stocks from the biotech sector are Immunocore Holdings plc IMCR, Spero Therapeutics, Inc. SPRO and Castle Biosciences, Inc. CSTL, each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.\nIn the past 60 days, estimates for Immunocore’s 2024 loss per share have narrowed from $1.79 to 94 cents. Loss per share estimates for 2025 have narrowed from $2.35 to $1.57 during the same time. Year to date, shares of IMCR have declined 53.9%.\nIMCR’s earnings beat estimates in two of the trailing four quarters while missing the same on the remaining two occasions, the average surprise being 25.57%.\nIn the past 60 days, estimates for Spero Therapeutics’ 2024 loss per share have narrowed from $1.59 to $1.29. Loss per share estimates for 2025 have narrowed from $1.54 to 79 cents during the same time. Year to date, shares of SPRO have declined 20.4%.\nSPRO’s earnings beat estimates in two of the trailing four quarters while missing the same on the remaining two occasions, the average surprise being 94.42%.\nIn the past 60 days, estimates for Castle Biosciences’ 2024 bottom line have moved up from a loss of 58 cents to earnings of 34 cents. Loss per share estimates for 2025 have narrowed from $2.13 to $1.84 during the same time. Year to date, shares of CSTL have surged 44.5%.\nCSTL’s earnings beat estimates in each of the trailing four quarters, the average surprise being 172.72%.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nBeam Therapeutics Inc. (BEAM) : Free Stock Analysis Report\nSpero Therapeutics, Inc. (SPRO) : Free Stock Analysis Report\nCastle Biosciences, Inc. (CSTL) : Free Stock Analysis Report\nImmunocore Holdings PLC Sponsored ADR (IMCR) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2490799937"}